Corporate Banner
Satellite Banner
Technology Networks Header
Wednesday, January 28, 2015
Technology Networks
 
Register | Sign in
Home Page > Latest Webcasts
  Webcasts
Scientific News
Noisy Data Facilitates Investigation of Breast Cancer Gene Expression
Study tested the potential of denoising autoencoders to identify and extract complex patterns from genomic data.
New 'Systems Genetics' Study Identifies Possible Target For Epilepsy Treatment
A single gene that coordinates a network of about 400 genes involved in epilepsy could be a target for new treatments, according to research.
First Major Analysis Of Human Protein Atlas Published
A research article published in Science presents the first major analysis based on the Human Protein Atlas, including a detailed picture of the proteins that are linked to cancer, the number of proteins present in the bloodstream, and the targets for all approved drugs on the market.
Insights Into A Rare Genetic Disease
Study shows mutation in NGLY1 gene is linked to a genetic disorder with severe consequences.
Hidden Cell Types Revealed
New statistical method for RNA-seq analysis identifies, corrects for hidden structure between cells.
Prognostic Test for E2F4 in Breast Cancer Developed
A gene signature in E2F4 has been identified which is predictive of estrogen receptor positive breast cancer.
UMMS Receives $6.1 M to Develop Model for Predicting Gene Expression
Insight into regulation of the genes that allow the immune system to recognize pathogens will help scientists rationally design new vaccines and prevent autoimmunity.
Project to Focus on Link Between Immune System and Brain Disorders
Researchers to investigate whether mood disorders, such as depression, and neurodegenerative diseases, such as Alzheimer’s, could be treated by targeting the immune system.
Predicting Antibiotic Resistance
A common set of features appear to be responsible for the development of resistance to several types of antibiotics.
Study Finds Genetic Clue To Menopause-Like Condition In Young Women
NIH-funded research may also contribute to understanding normal menopause.
Scroll Up
Scroll Down
Return
Multi Center Validation of a New Molecular Diagnostic Assay for Accurate and Rapid Screening of JAK2 V617F Mutation
Fabienne Hermitte, CSO, Ipsogen, speaking at the Molecular Diagnostics World Congress 2007
Date Posted: Monday, May 19, 2008
Print Page

For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here



IPSOGEN Expands its U.S. Presence through Licensing Agreement with Quest Diagnostics
Ipsogen entered a non-exclusive license agreement with Quest for the use of the JAK2 V617F mutation in Quest Diagnostic's laboratory developed tests.
Tuesday, October 07, 2008
IPSOGEN Expands its U.S. Presence Through Licensing Agreement with Quest Diagnostics
Ipsogen SA, a molecular diagnostic company specialized in the development, manufacturing and commercialization of diagnostic assays for breast cancer and leukemia, today announced a non-exclusive license agreement with Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, for the use of the JAK2 V617F mutation in Quest Diagnostic's laboratory developed tests.
Monday, October 06, 2008
Ipsogen Launches MapQuant Dx™ Genomic Grade Test to Analyze Chemotherapy Results
The Company expects that by improving the accuracy of tumor grading, the test could spare tens of thousands chemotherapy treatments per year.
Monday, June 02, 2008
Ipsogen Announces Three Studies at the American Society of Clinical Oncology Meeting
The results from the studies extend the utility of the Genomic Grade index for predicting response to chemotherapy in breast cancer.
Monday, May 26, 2008
IPSOGEN Licenses the Genomic Grade™ to Improve Breast Cancer Diagnosis & Treatment Decision
IPSOGEN signed a license agreement with Universite Libre de Bruxelles (ULB), Belgium for the worldwide and exclusive rights on the Genomic Grade™.
Monday, January 28, 2008
Ipsogen Reports Recommendation of JAK2V617F Mutation Screening in WHO 2008 Criteria and Point-of-Care Diagnostic Algorithms
The 2008 revision of the WHO document on the classification of CMPDs has incorporated new information on the molecular pathogenesis of BCR–ABL negative myeloproliferative disorders including the screening for JAK2V617F mutation.
Tuesday, January 22, 2008
IPSOGEN Grants Labcorp License for Leukemia Molecular Diagnostic Assay in USA
IPSOGEN grants LabCorp non-exclusive rights to offer an assay for the diagnosis of a group of leukemias caused by JAK2 gene variations.
Tuesday, September 11, 2007
Ipsogen Grants Exclusive License to Warnex to Market a Leukemia Molecular Diagnostic Service in Canada
Ipsogen grants Warnex exclusive rights to market a service for the diagnosis and the classification of a group of leukemias.
Thursday, August 16, 2007
Ipsogen Presents Breast Cancer Biomarker Results at the EBCC 5
These results concern the identification on 323 patient samples.
Monday, February 27, 2006
 
Skyscraper Banner
SELECTBIO Market Reports
LabTube - Videos for the Scientific Community
eposters - The Online Journal of Scientific Posters
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn